PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24840315-1 2015 BACKGROUND & AIMS: Aim of this study was to investigate whether a potential association exists between several single nucleotide polymorphisms (SNPs) of the IL-28B gene (rs12979860, rs1188122, rs8099917, rs8105790, rs12980275) and HBsAg persistence. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 161-167 30398404-5 2018 RESULTS & CONCLUSION: Multinominal logistic regression analyses revealed that both genders favor IL28B rs12979860 CT genotype (OR: 4.80; CI: 2.22-10.35; p = 0.0005) and (OR: 3.47; CI: 1.63-7.43; p = 0.001) for male and female, respectively, are significant in spontaneous clearance of HCV infection. Adenosine Monophosphate 9-12 interferon lambda 3 Homo sapiens 101-106 25041342-1 2015 BACKGROUND & AIMS: Several genome-wide association studies have revealed that HLA-DP/DQ, STAT4 and IL-28B associated with liver diseases. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 103-109 23522062-1 2013 BACKGROUND & AIMS: Both polymorphisms in the IL28B gene locus and ISG expression levels are associated with the outcome of hepatitis C virus (HCV) infection. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 49-54 25039676-1 2015 BACKGROUND & AIMS: Different prevalence of favourable IL28BCC genotype have been reported in studies performed in different countries around the world. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 58-62 25283962-1 2014 BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 192-204 25283962-1 2014 BACKGROUND & AIMS: In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, DeltaG/TT) of a new gene, designated IFN lambda-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 261-266 24768758-1 2014 BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) near the interferon lambda 3 (IFNL3, previously known as IL28B) region are the strongest baseline predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin therapy in hepatitis C virus (HCV) genotype 1 infection. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 92-97 24118788-1 2014 BACKGROUND & AIMS: Several genome-wide association studies have shown that genetic variations in the chromosomal region containing interleukin-28B (IL28B) gene are associated with response to treatment in hepatitis C virus (HCV) infection. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 152-157 24637774-1 2014 BACKGROUND & AIMS: IL28B polymorphisms were shown to be strongly associated with the response to interferon therapy in chronic hepatitis C (CHC) and spontaneous viral clearance. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 23-28 23978349-1 2014 BACKGROUND & AIMS: Interleukin (IL)-28B (interferon-lambda 3) genotype is the strongest predictor of response of patients with hepatitis C virus (HCV) infection to antiviral therapy. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 23-43 23978349-1 2014 BACKGROUND & AIMS: Interleukin (IL)-28B (interferon-lambda 3) genotype is the strongest predictor of response of patients with hepatitis C virus (HCV) infection to antiviral therapy. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 45-64 23850880-1 2013 BACKGROUND & AIMS: IL28B polymorphisms, jaundice, decline in HCV-RNA, IP-10, and gender have been proposed to be indicative of spontaneous clearance of acute hepatitis C virus infection. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 23-28 24204859-1 2013 BACKGROUND & AIMS: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other biochemical or histological baseline parameters. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 51-70 24204859-1 2013 BACKGROUND & AIMS: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other biochemical or histological baseline parameters. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 77-82 24204859-1 2013 BACKGROUND & AIMS: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other biochemical or histological baseline parameters. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 84-89 22634340-0 2012 Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. BACKGROUND & AIMS: Insulin resistance, fibrosis and steatosis are established predictors of response to peg-interferon/ribavirin therapy in chronic hepatitis C (CHC). Adenosine Monophosphate 108-111 interferon lambda 3 Homo sapiens 19-24 23321318-1 2013 BACKGROUND & AIMS: Nucleotide polymorphisms upstream of the interleukin 28B (IL28B) gene are strongly associated with hepatitis C virus (HCV) clearance in treatment-naive patients treated with peginterferon/ribavirin (PegIFN/RBV). Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 81-86 23333445-1 2013 BACKGROUND & AIMS: IL28B single nucleotide polymorphisms are strongly associated with spontaneous HCV clearance and treatment response in non-transplant populations. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 23-28 23121166-9 2013 The analyses also showed that degree of steatosis, HOMA-IR >2, mild fibrosis and IL28B CC genotype were significantly related to SVR in patients infected with HCV genotypes 1&4, but not in those with genotypes 2&3. Adenosine Monophosphate 178-181 interferon lambda 3 Homo sapiens 84-89 21354446-0 2011 IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) associated with IL28B influence the outcome of peginterferon-alpha/ribavirin therapy of chronic hepatitis C virus (HCV) infection. Adenosine Monophosphate 115-118 interferon lambda 3 Homo sapiens 0-5 21703198-0 2011 Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. BACKGROUND & AIMS: IL28B polymorphisms have been associated with both treatment induced and spontaneous clearance of hepatitis C virus (HCV). Adenosine Monophosphate 129-132 interferon lambda 3 Homo sapiens 11-16 21951981-0 2012 IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections. Adenosine Monophosphate 118-121 interferon lambda 3 Homo sapiens 0-5 21951981-0 2012 IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)28B gene have been associated with pegylated-interferon (PEG-IFN) and ribavirin treatment response mainly in genotype 1 HCV infections. Adenosine Monophosphate 118-121 interferon lambda 3 Homo sapiens 164-183 21889467-1 2012 BACKGROUND & AIMS: Recipient and donor IL28B polymorphisms seem to play an important role in the response to hepatitis C treatment after liver transplantation (LT). Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 43-48 22192885-1 2012 BACKGROUND & AIMS: Single nucleotide polymorphisms (SNPs) in IL28B and serum levels of interferon gamma inducible protein 10 (IP-10) predict outcomes of antiviral therapy in patients with chronic hepatitis C. We associated IL28B SNPs rs12979860 and rs8099917, along with serum levels of IP-10, with outcomes of patients with acute hepatitis C (AHC). Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 65-70 21147186-1 2011 BACKGROUND & AIMS: Recent studies have described a major impact of genetic variations near the IL28B gene on the natural course and outcome of antiviral therapy in chronic hepatitis C. We therefore, aimed to explore the impact of donor and recipient genotypes of these polymorphisms on hepatitis C virus (HCV) liver graft reinfection. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 99-104 21600205-1 2011 BACKGROUND & AIMS: Polymorphisms in the interleukin-28B (IL28B) gene are associated with outcomes from infection with hepatitis C virus (HCV). Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 61-66 21145807-1 2011 BACKGROUND & AIMS: Polymorphisms of the IL28B gene (rs12979860 and rs8099917) are associated with high sustained virological response (SVR) rates in HCV genotype 1 patients. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 44-49 21146242-1 2011 BACKGROUND & AIMS: A single nucleotide polymorphism (rs12979860 C/T) 3kb upstream of the interleukin 28B (IL-28B) gene was shown to be associated with hepatitis C clearance. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 110-116 21112657-1 2011 BACKGROUND & AIMS: Genetic variation in the interleukin 28B (IL28B) gene has been associated with the response to interferon-alfa/ribavirin therapy in hepatitis C virus (HCV) genotype 1-infected patients. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 65-70 20637200-1 2010 BACKGROUND & AIMS: A single nucleotide polymorphism (SNP) upstream of the IL28B gene has been associated with response of patients with chronic hepatitis C to therapy with pegylated interferon and ribavirin and also with spontaneous clearance of acute hepatitis C in a heterogeneous population. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 78-83 20708617-0 2010 Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. BACKGROUND & AIMS: Patients with hepatitis C virus (HCV)-related liver disease frequently undergo orthotopic liver transplantation, but recurrent hepatitis C is still a major cause of morbidity. Adenosine Monophosphate 152-155 interferon lambda 3 Homo sapiens 12-17 21145800-1 2011 BACKGROUND & AIMS: Common genetic variation within the IL28 locus has been found to influence the effect of peg-interferon and ribavirin combination therapy against chronic hepatitis C virus (HCV) infection. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 59-63 20576307-1 2010 BACKGROUND & AIMS: A common genetic variation at the IL28 locus has been found to affect the response of peg-interferon and ribavirin combination therapy against chronic hepatitis C virus (HCV) infection. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 57-61 20399780-1 2010 BACKGROUND & AIMS: We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic hepatitis C virus genotype 1 (HCV-1) infection. Adenosine Monophosphate 12-15 interferon lambda 3 Homo sapiens 73-93